Product Overview & Details for Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS®) 2022 (Videos)

Founded in 1995, Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS®) is a community of leaders from the United States and Canada who are dedicated to the treatment and research in MS and other demyelinating diseases. ACTRIMS focuses on knowledge dissemination, education and collaboration among disciplines.

Thursday, February 24, 2022

8:00 – 9:00 am
BREAKFAST

9:00 – 10:00 am
KJ1. Opening Address & Kenneth P. Johnson Memorial Lecture
Chairs: Jeffrey A. Cohen, Cleveland Clinic and Anne Cross, Washington University in St. Louis

Lecturer: Ruth Ann Marrie, University of Manitoba

10:00 – 11:35 am
S1. Session 1 – Emerging Concepts in MS
Chairs: Daniel Reich, National Institutes of Health and Catherine Larochelle, Université de Montréal
Theme: Highlighting cutting-edge studies that inform our understanding of the pathogenic mechanisms in MS, introduce novel measures to capture disease activity, and advance treatment options for affected individuals. This session will be comprised of six platform presentations by Young Investigators selected from submitted abstracts.

10:00 – 10:05 am
Introduction

10:05 – 10:20 am
S1.1 Deep Learning Prediction of Response to Disease Modifying Therapy in Primary Progressive Multiple Sclerosis
Jean-Pierre Falet, McGill University

10:20 – 10:35 am
S1.2 The Gut Microbe in Pediatric-Onset MS: A Matched Case-Control Study
Xiaoyuan Zhou, University of California, San Francisco

10:35 – 10:50 am
S1.3 Fibulin-2 as a Potent Extracellular Matrix Inhibitor of Remyelination in MS
Samira Ghorbani, University of Calgary

10:50 – 11:05 am
S1.4 Divergent Role of the Classic Complement Pathway in Two Murine Models of Multiple Sclerosis
Michael Linzey, Darmouth College

11:05 – 11:20 am
S1.5 Diagnostic Potential of Paramagnetic Rim Lesions for MS in a Multicenter Setting
Brian Renner, Cedar-Sinai

11:20 – 11:35 am
S1.6 Histopathological Assessment of Myelinated White Matter T2 Hyperintensities in Myelocortical Multiple Sclerosis
Vikas Singh, Cleveland Clinic

11:35 am – 1:00 pm
LUNCH

12:30 – 12:50 pm
PT1. Industry Supported Product Theater*

Clinical Advances in Multiple Sclerosis: Addressing Unmet Needs
This activity is an independently supported presentation provided by Janssen Pharmaceuticals, Inc.

1:00 – 2:30 pm
S2. Session 2 – Biomarkers of MS Susceptibility/Prodrome
Chairs: Mitzi Joi Williams, Joi Life Wellness and Adil Harroud, University of California, San Francisco

Theme: Understanding MS susceptibility and MS prodromal phase through genetics, imaging, cerebrospinal fluid and the microbiota.

1:00 – 1:05 pm
Introduction

1:05 – 1:20 pm
S2.1 Translating Genetic Associations with MS Susceptibility into a Framework to Manage the Presymptomatic Phase of MS

Phil De Jager, Columbia University

1:20 – 1:35 pm
S2.2 Impact of Fecal Transplant on Cortical Pathology in an Animal Model of MS

Jen Gommerman, University of Toronto

1:35 – 1:50 pm
S2.3 Imaging Biomarkers of RIS/MS Prodrome

Jiwon Oh, University of Toronto

1:50 – 2:05 pm
S2.4 What Can Studies of Twins CSF Reveal about Prodrome of MS?

Eduardo Beltran, University of Munich

2:05 – 2:30 pm
Q&A Discussion

2:30 – 3:35 pm
CE1. Cutting Edge Developments 1

Chairs: Bianca Weinstock-Guttman, University of Buffalo and V. Wee Yong, University of Calgary

Theme: Cutting-edge platform presentations selected from the ACTRIMS abstract submissions. Each presenter will have 15 minutes total for their presentation –   12 minutes for the presentation and 3 minutes for Q&A.

2:30 – 2:35 pm
Introduction

2:35 – 2:50 pm
CE1.1 Aged CNS-Resident Cells Promote a Non-Remitting Course of Experimental Autoimmune  Encephalomyelitis

Jeffrey Atkinson, The Ohio State

2:50 – 3:05 pm
CE1.2 Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Sclerosis: Long Term Follow Up of the Ottawa Cohort

Francis Brunet,

3:05 – 3:20 pm
CE1.3 Effectiveness of the Bruton’s Tyrosine Kinase Inhibitor Evobruntinib in a Novel Model for Compartmentalized Neuroinflammation in  Multiple Sclerosis

Jorge Alvarez, University of Pennsylvania

3:20 – 3:35 pm
CE1.4 Ageing Promotes Non-Remitting Experimental Autoimmune Encephalomyelitis with Persistent Meningeal Inflammation and Subpial  Demyelination in A/T SJL/J Mice

Michelle Zuo, University of Toronto

3:35 – 4:00 pm
BREAK

4:00 – 5:15 pm
AP2. NAIMS Symposium

5:15 – 6:45 pm
Poster Session 1

Presentations will begin at 5:30, with even-numbered posters presenting from 5:30-6:00pm and odd-numbered posters presenting from 6:00-6:30pm.

6:45 – 9:00 pm
ACTRIMS Lounge Open

6:45 – 8:30 pm
iWiMS Reception

7:00 – 8:00 pm
SS1. Industry Supported CE Satellite Symposium*

Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Racial-Ethnic Patient Populations

This CE activity is provided by Physicians’ Education Resource, LLC. This independent Industry Supported Satellite Symposium is supported by educational grants  from Biogen and Sanofi. 

Friday, February 25, 2022

7:00 – 9:00 am	BREAKFAST
7:30 – 8:30 am	SS2. Industry Supported CE Satellite Symposium* Practical Applications of S1P Therapeutics for the Treatment of Relapsing Forms of Multiple Sclerosis This CE activity is provided by AcademicCME. This independent Industry Supported Satellite Symposium is supported by an educational grant from Bristol Myers Squibb.
8:30 – 9:00 am	BREAK
9:00 – 10:30 am	S3. Session 3 – Biomarkers Related to MS Pathophysiology and MS Diagnosis Chairs: Lauren Krupp, NYU Langone and Kevin Patel, University of California, Los Angeles Theme: Understanding the pathophysiology of adult and pediatric MS using CSF, imaging and ophthalmologic biomarkers.
	9:00 – 9:05 am	Introduction
	9:05 – 9:20 am	S3.1 Single Cell RNA Sequencing in MS CSF: Beyond Oligoclonal Bands Claudia Cantoni, Washington University
	9:20 – 9:35 am	S3.2 Using the Central Vein Sign and Cortical Lesions to Diagnose MS Pascal Sati, Cedar Sinai
	9:35 – 9:50 am	S3.3 OCT in the Diagnosis of Afferent Visual Pathway Problems in MS Fiona Costello, University of Calgary
	9:50 – 10:05 am	S3.4 Biomarkers of MS Diagnosis in Children Giulia Fadda, McGill University
	10:05 – 10:30 am	Q&A Discussion
10:30 – 11:35 am	CE2. Cutting Edge Developments 2 Chairs: Robert Naismith, Washington University at St. Louis and Myla Goldman, VCU Health Theme: Cutting-edge platform presentations selected from the ACTRIMS abstract submissions. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.
	10:30 – 10:35 am	Introduction
	10:35 – 10:50 am	CE2.1 Heterogeneity of Myeloid Cells During CNS Autoimmunity Navid Manoucheri, UT Southwestern – Dallas
	10:50 – 11:05 am	CE2.2 Spinal Cord Atrophy Predicts Silent Progression in Relapse-onset Multiple Sclerosis Antje Bischof, University of California, San Francisco
	11:05 – 11:20 am	CE2.3 Cortical Lesion Burden is Associated with Worsening Disability Over Time and Conversion to Progressive MS Williams Mullins, NIH
	11:20 – 11:35 am	CE2.4 Patterns of Disease-Modifying Treatment Use and Sociodemographic Characteristics in Multiple Sclerosis by Race and Ethnicity Carlos Pérez, The University of Texas Health Science Center at Houston
11:35 am – 1:00 pm	LUNCH
11:50 am – 12:10 pm	PT2. Industry Supported Product Theater* The Role of the Complement System in the Innate and Adaptive Immune Responses This activity is an independently supported presentation provided by Alexion, AstraZeneca Rare Disease
12:30 – 12:50 pm	PT3. Industry Supported Product Theater* The CNS in MS: A Brain-First Perspective This activity is an independently supported presentation provided by Bristol Myers Squibb.
1:00 – 2:30 pm	S4. Session 4 – Prognostic Biomarkers of MS and NMOSD Chairs: Christina Azevedo, University of Southern California, and Sarah Morrow, Western University Theme: Using demographic, imaging, blood and cerebrospinal fluid and electronic health records for prognostication in MS and in NMOSD.
	1:00 – 1:05 pm	Introduction
	1:05 – 1:20 pm	S4.1 Blood and CSF Biomarkers of Prognosis and Patient Outcomes Tanuja Chitnis, Brigham and Women’s Hospital
	1:20 – 1:35 pm	S4.2 The Interactions of Sex, Hormones and Age in MS Prognosis Burcu Zeydan, Mayo Clinic
	1:35 – 1:50 pm	S4.3 Electronic Health Records and Prognostic Marker of Outcome and Platform for Clinical Discovery in MS Zongqi Xia, University of Pittsburgh
	1:50 – 2:05 pm	S4.4 Prognostic Biomarkers of NMOSD Bruce Cree, University of California, San Francisco
	2:05 – 2:30 pm	Q&A Discussion
2:30 – 3:30 pm	NMSS Barancik Award Presentation and Talk
3:30 – 4:00 pm	BREAK
3:35 – 3:55 pm	PT4. Industry Supported Product Theater* Understanding the Proposed Mechanism of Action of an Oral Dosing Therapy This activity is an independently supported presentation provided by EMD Serono.
4:00 – 5:15 pm	AP3. IMSVISUAL Symposium
5:15 – 6:45 pm	Poster Session 2 Presentations will begin at 5:30, with even-numbered posters presenting from 5:30-6:00 pm and odd-numbered posters presenting from 6:00-6:30 pm.
6:45 – 9:00 pm	ACTRIMS Lounge Open Continue the conversation and connect with others in the casual, relaxed ACTRIMS Lounge.
7:00 – 8:00 pm	SS3. Industry Supported CE Satellite Symposium* Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now This CE activity is jointly provided by Medical Learning Institute, Inc and PVI, PeerView Institute for Medical Education. This independent Industry Supported Satellite Symposium is supported by educational grants from EMD Serono and Sanofi.*

Saturday, February 26, 2022

8:45 – 9:00 am	BREAKFAST
9:00 – 10:30am	S5. Session 5 – Biomarkers of Progressive MS Chairs: Nathalie Arbour, Université de Montréal and Christopher Hemond, University of Massachusetts Medical School Theme: Animal models of progressive MS, blood and imaging biomarkers of progressive MS, and outcome measures that can be used in clinical trials in progressive MS.
	9:00 – 9:05am	Introduction
	9:05 – 9:20am	S5.1 Biological Sex as a Determinant in Inflammatory T Cell Responses in Chronic CNS Autoimmunity Manu Rangachari, Laval University
	9:20 – 9:35am	S5.2 miRNA Biomarkers of Neuronal Damage Underlying Neurodegeneration in MS Alyson Fournier, McGill University
	9:35 – 9:50am	S5.3 Imaging Biomarkers of Progression Martina Absinta, Johns Hopkins University
	9:50 – 10:05am	S5.4 Outcome Measures for Trials of Progressive MS Robert Fox, Cleveland Clinic
	10:05 – 10:30am	Q&A Discussion
10:30 – 11:35 am	CE3. Cutting Edge Developments 3 Chairs: Andrew Goodman, University of Rochester and Amit Bar-Or, University of Pennsylvania Theme: Cutting-edge platform presentations selected from the ACTRIMS abstract submissions. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.
	10:30 – 10:35 am	Introduction
	10:35 – 10:50 am	CE3.1 Economic Burden of Multiple Sclerosis in 2019 Bruce Bebo, National MS Society
	10:50 – 11:05 am	CE3.2 Cognitive Functioning in MS Improves with At-Home Online Training Paired with Transcranial Direct Current Stimulation (tDCS): Results from a Sham-Controlled Randomized Clinical Trial Leigh Charvet, New York University
	11:05 – 11:20 am	CE3.3 Prior Optic Neuritis Detection on Peripapillary Ring Scans using Dilated Residual Networks Seyedamirhosein Motamedi, Charité Berlin
	11:20 am – 11:35 am	CE3.4 Serum Neurofilament as a Predictor of 10-Year Gray Matter Atrophy and Clinical Disability in Multiple Sclerosis – A Longitudinal Study Ingrid Lie, University of Bergen
11:35 am- 1:00 pm	LUNCH
1:00 – 2:30pm	S6. Session 6 – Biomarkers of Remyelination, Repair and Treatment Chairs: Jack Antel, McGill University and Jason Plemel, University of Alberta Theme: Uses of animal models, imaging, and fluid biomarkers to study remyelination and repair of the central nervous system.
	1:00 – 1:05 pm	Introduction
	1:05 – 1:20 pm	S6.1 Biomarkers of Remyelination in Animal Models Ian Duncan, University of Wisconsin – Madison
	1:20 – 1:35 pm	S6.2 Imaging Biomarkers of Demyelination and Remyelination Shannon Kolind, University of British Columbia
	1:35 – 1:50 pm	S6.3 Blood Neurofilament Light Levels of Monitoring Treatment Effects in Multiple Sclerosis Enrique Alvarez, University of Colorado
	1:50 – 2:05 pm	S6.4 Immunologic Networks to Predict Treatment Response in Patients with MS David Hafler, Yale University
	2:05 – 2:30 pm	Q&A Discussion
2:30 – 2:45 pm	Awards Presentation & Closing Remarks
2:45 – 3:00 pm	BREAK
3:00 – 4:00 pm	SS4. Industry Supported CE Satellite Symposium* Detecting and Managing Neuromyelitis Optica Spectrum Disorder: What Can You Do to Achieve Early Diagnosis and Improved Patient Outcomes in Your Clinical Practice? This CE activity is provided by Med Learning Group. This independent Industry Supported Satellite Symposium is supported by an educational grant from Genentech, a Member of the Roche Group.

View cart “The Pass Machine : Sleep Medicine Board Review Course” has been added to your cart.

Back to products

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS®) 2022 (Videos)

Description

7:00 – 9:00 am	BREAKFAST
7:30 – 8:30 am	SS2. Industry Supported CE Satellite Symposium* Practical Applications of S1P Therapeutics for the Treatment of Relapsing Forms of Multiple Sclerosis This CE activity is provided by AcademicCME. This independent Industry Supported Satellite Symposium is supported by an educational grant from Bristol Myers Squibb.
8:30 – 9:00 am	BREAK
9:00 – 10:30 am	S3. Session 3 – Biomarkers Related to MS Pathophysiology and MS Diagnosis Chairs: Lauren Krupp, NYU Langone and Kevin Patel, University of California, Los Angeles Theme: Understanding the pathophysiology of adult and pediatric MS using CSF, imaging and ophthalmologic biomarkers.
	9:00 – 9:05 am	Introduction
	9:05 – 9:20 am	S3.1 Single Cell RNA Sequencing in MS CSF: Beyond Oligoclonal Bands Claudia Cantoni, Washington University
	9:20 – 9:35 am	S3.2 Using the Central Vein Sign and Cortical Lesions to Diagnose MS Pascal Sati, Cedar Sinai
	9:35 – 9:50 am	S3.3 OCT in the Diagnosis of Afferent Visual Pathway Problems in MS Fiona Costello, University of Calgary
	9:50 – 10:05 am	S3.4 Biomarkers of MS Diagnosis in Children Giulia Fadda, McGill University
	10:05 – 10:30 am	Q&A Discussion
10:30 – 11:35 am	CE2. Cutting Edge Developments 2 Chairs: Robert Naismith, Washington University at St. Louis and Myla Goldman, VCU Health Theme: Cutting-edge platform presentations selected from the ACTRIMS abstract submissions. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.
	10:30 – 10:35 am	Introduction
	10:35 – 10:50 am	CE2.1 Heterogeneity of Myeloid Cells During CNS Autoimmunity Navid Manoucheri, UT Southwestern – Dallas
	10:50 – 11:05 am	CE2.2 Spinal Cord Atrophy Predicts Silent Progression in Relapse-onset Multiple Sclerosis Antje Bischof, University of California, San Francisco
	11:05 – 11:20 am	CE2.3 Cortical Lesion Burden is Associated with Worsening Disability Over Time and Conversion to Progressive MS Williams Mullins, NIH
	11:20 – 11:35 am	CE2.4 Patterns of Disease-Modifying Treatment Use and Sociodemographic Characteristics in Multiple Sclerosis by Race and Ethnicity Carlos Pérez, The University of Texas Health Science Center at Houston
11:35 am – 1:00 pm	LUNCH
11:50 am – 12:10 pm	PT2. Industry Supported Product Theater* The Role of the Complement System in the Innate and Adaptive Immune Responses This activity is an independently supported presentation provided by Alexion, AstraZeneca Rare Disease
12:30 – 12:50 pm	PT3. Industry Supported Product Theater* The CNS in MS: A Brain-First Perspective This activity is an independently supported presentation provided by Bristol Myers Squibb.
1:00 – 2:30 pm	S4. Session 4 – Prognostic Biomarkers of MS and NMOSD Chairs: Christina Azevedo, University of Southern California, and Sarah Morrow, Western University Theme: Using demographic, imaging, blood and cerebrospinal fluid and electronic health records for prognostication in MS and in NMOSD.
	1:00 – 1:05 pm	Introduction
	1:05 – 1:20 pm	S4.1 Blood and CSF Biomarkers of Prognosis and Patient Outcomes Tanuja Chitnis, Brigham and Women’s Hospital
	1:20 – 1:35 pm	S4.2 The Interactions of Sex, Hormones and Age in MS Prognosis Burcu Zeydan, Mayo Clinic
	1:35 – 1:50 pm	S4.3 Electronic Health Records and Prognostic Marker of Outcome and Platform for Clinical Discovery in MS Zongqi Xia, University of Pittsburgh
	1:50 – 2:05 pm	S4.4 Prognostic Biomarkers of NMOSD Bruce Cree, University of California, San Francisco
	2:05 – 2:30 pm	Q&A Discussion
2:30 – 3:30 pm	NMSS Barancik Award Presentation and Talk
3:30 – 4:00 pm	BREAK
3:35 – 3:55 pm	PT4. Industry Supported Product Theater* Understanding the Proposed Mechanism of Action of an Oral Dosing Therapy This activity is an independently supported presentation provided by EMD Serono.
4:00 – 5:15 pm	AP3. IMSVISUAL Symposium
5:15 – 6:45 pm	Poster Session 2 Presentations will begin at 5:30, with even-numbered posters presenting from 5:30-6:00 pm and odd-numbered posters presenting from 6:00-6:30 pm.
6:45 – 9:00 pm	ACTRIMS Lounge Open Continue the conversation and connect with others in the casual, relaxed ACTRIMS Lounge.
7:00 – 8:00 pm	SS3. Industry Supported CE Satellite Symposium* Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now This CE activity is jointly provided by Medical Learning Institute, Inc and PVI, PeerView Institute for Medical Education. This independent Industry Supported Satellite Symposium is supported by educational grants from EMD Serono and Sanofi.*

8:45 – 9:00 am	BREAKFAST
9:00 – 10:30am	S5. Session 5 – Biomarkers of Progressive MS Chairs: Nathalie Arbour, Université de Montréal and Christopher Hemond, University of Massachusetts Medical School Theme: Animal models of progressive MS, blood and imaging biomarkers of progressive MS, and outcome measures that can be used in clinical trials in progressive MS.
	9:00 – 9:05am	Introduction
	9:05 – 9:20am	S5.1 Biological Sex as a Determinant in Inflammatory T Cell Responses in Chronic CNS Autoimmunity Manu Rangachari, Laval University
	9:20 – 9:35am	S5.2 miRNA Biomarkers of Neuronal Damage Underlying Neurodegeneration in MS Alyson Fournier, McGill University
	9:35 – 9:50am	S5.3 Imaging Biomarkers of Progression Martina Absinta, Johns Hopkins University
	9:50 – 10:05am	S5.4 Outcome Measures for Trials of Progressive MS Robert Fox, Cleveland Clinic
	10:05 – 10:30am	Q&A Discussion
10:30 – 11:35 am	CE3. Cutting Edge Developments 3 Chairs: Andrew Goodman, University of Rochester and Amit Bar-Or, University of Pennsylvania Theme: Cutting-edge platform presentations selected from the ACTRIMS abstract submissions. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.
	10:30 – 10:35 am	Introduction
	10:35 – 10:50 am	CE3.1 Economic Burden of Multiple Sclerosis in 2019 Bruce Bebo, National MS Society
	10:50 – 11:05 am	CE3.2 Cognitive Functioning in MS Improves with At-Home Online Training Paired with Transcranial Direct Current Stimulation (tDCS): Results from a Sham-Controlled Randomized Clinical Trial Leigh Charvet, New York University
	11:05 – 11:20 am	CE3.3 Prior Optic Neuritis Detection on Peripapillary Ring Scans using Dilated Residual Networks Seyedamirhosein Motamedi, Charité Berlin
	11:20 am – 11:35 am	CE3.4 Serum Neurofilament as a Predictor of 10-Year Gray Matter Atrophy and Clinical Disability in Multiple Sclerosis – A Longitudinal Study Ingrid Lie, University of Bergen
11:35 am- 1:00 pm	LUNCH
1:00 – 2:30pm	S6. Session 6 – Biomarkers of Remyelination, Repair and Treatment Chairs: Jack Antel, McGill University and Jason Plemel, University of Alberta Theme: Uses of animal models, imaging, and fluid biomarkers to study remyelination and repair of the central nervous system.
	1:00 – 1:05 pm	Introduction
	1:05 – 1:20 pm	S6.1 Biomarkers of Remyelination in Animal Models Ian Duncan, University of Wisconsin – Madison
	1:20 – 1:35 pm	S6.2 Imaging Biomarkers of Demyelination and Remyelination Shannon Kolind, University of British Columbia
	1:35 – 1:50 pm	S6.3 Blood Neurofilament Light Levels of Monitoring Treatment Effects in Multiple Sclerosis Enrique Alvarez, University of Colorado
	1:50 – 2:05 pm	S6.4 Immunologic Networks to Predict Treatment Response in Patients with MS David Hafler, Yale University
	2:05 – 2:30 pm	Q&A Discussion
2:30 – 2:45 pm	Awards Presentation & Closing Remarks
2:45 – 3:00 pm	BREAK
3:00 – 4:00 pm	SS4. Industry Supported CE Satellite Symposium* Detecting and Managing Neuromyelitis Optica Spectrum Disorder: What Can You Do to Achieve Early Diagnosis and Improved Patient Outcomes in Your Clinical Practice? This CE activity is provided by Med Learning Group. This independent Industry Supported Satellite Symposium is supported by an educational grant from Genentech, a Member of the Roche Group.

Category: Neurology Tags: ACTRIMS 2022 videos, ACTRIMS annual conference, ACTRIMS collaboration opportunities, ACTRIMS conference highlights, ACTRIMS conference materials, ACTRIMS interdisciplinary collaboration, ACTRIMS knowledge dissemination, ACTRIMS meeting videos, ACTRIMS online course, ACTRIMS treatment updates, ACTRIMS United States and Canada, Animal Models, at-home cognitive training MS, autologous hematopoietic stem cell transplantation MS, Bruton's tyrosine kinase inhibitor MS, BTK inhibitors multiple sclerosis, Central Vein Sign, Clinical Trials, CNS autoimmunity myeloid cells, Cognitive Function, Cortical Lesions, CSF Biomarkers, CSF biomarkers in MS, demyelinating diseases education, demyelinating diseases research, Demyelination, Disease Modifying Therapy, disease-modifying treatments MS, Electronic Health Records, emerging MS concepts, Genetics, Gray Matter Atrophy, Gut Microbiome, Imaging Biomarkers, Immunologic Networks, miRNA, MS and demyelinating conditions research, MS and demyelinating diseases treatment advancements, MS Biomarkers, MS clinical research updates, MS clinical research videos, MS collaborative research, MS complement pathway, MS cortical lesion disability, MS education and knowledge dissemination, MS education resources, MS genetic susceptibility, MS imaging biomarkers, MS interdisciplinary collaboration, MS Pathogenic Mechanisms, MS prodromal phase, MS Prodrome, MS remyelination biomarkers, MS remyelination inhibitors, MS research and treatment, MS specialists conference, MS spinal cord atrophy, MS Susceptibility, MS treatment advancements, MS treatment options, MS treatment updates 2022, Multiple Sclerosis, Multiple Sclerosis research conference, multiple sclerosis research developments, myelocortical MS, Myeloid Cells, Neurodegeneration, neuromyelitis optica spectrum disorder, NMOSD, NMOSD detection and management, North American MS research community, North American MS specialists, novel MS disease activity measures, Optical Coherence Tomography, Outcome Measures, paramagnetic rim lesions MS diagnosis, Pediatric-Onset MS, pediatric-onset MS gut microbes, Primary Progressive MS, primary progressive MS deep learning, Prognostic Biomarkers, prognostic biomarkers MS, Progressive MS, progressive MS clinical trials, Relapse-Onset MS, Remyelination, Ruth Ann Marrie University of Manitoba, S1P therapeutics MS, Serum Neurofilament, serum neurofilament MS prognosis, Sex Differences, Silent Progression, Single Cell RNA Sequencing, Sociodemographic Characteristics, Spinal Cord Atrophy, tDCS, treatment research in Multiple Sclerosis, Treatment Response

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS®) 2022 (Videos)

Product Overview & Details for Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS®) 2022 (Videos)

ACTRIMS Forum 2022

Biomarkers in MS

Thursday, February 24, 2022

Friday, February 25, 2022

Saturday, February 26, 2022

Harvard Neurological Emergencies 2021

Electrodiagnostic Medicine and Neuromuscular Disorders – A Case-Based Approach 2020

Cleveland Clinic Epilepsy Update & Review 2018

The American Academy of Neurology course AAN Annual Meeting On Demand 2019

2020 Stroke Imaging and Intervention

UCSF Neuro and Musculoskeletal Imaging 2019

2020 Neuroradiology in Clinical Practice

Medmastery 2020

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS®) 2022 (Videos)

Product Overview & Details for Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS®) 2022 (Videos)

ACTRIMS Forum 2022

Biomarkers in MS

Thursday, February 24, 2022

Friday, February 25, 2022

Saturday, February 26, 2022

Related products

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS®) 2022 (Videos)